S. Koski

发表

Improving the care of colorectal cancer patients

S. Koski, 2009 .

A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer.

J. Mackey, C. Cass, M. Sawyer, 2016, Clinical breast cancer.

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

R. Salazar, E. Van Cutsem, G. Bodoky, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

W. Scheithauer, L. Saltz, S. Clarke, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results

W. Scheithauer, L. Saltz, S. Clarke, 2011, British Journal of Cancer.

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

W. Scheithauer, L. Saltz, S. Clarke, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of colorectal cancer diagnosis among younger adults in a real-world, population-based cohort.

O. Abdel-Rahman, S. Koski, H. Karachiwala, 2021, Future oncology.

Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.

J. Mackey, M. Smylie, H. Au, 2004, Clinical Breast Cancer.

Cisplatin-Based versus Carboplatin-Based Chemotherapy for Extrapulmonary Neuroendocrine Carcinomas: A Real-World Study

O. Abdel-Rahman, S. Koski, 2021, Neuroendocrinology.

Vitamin and herbal supplements’ use among patients with advanced gastrointestinal cancers included in eight clinical trials

J. Spratlin, O. Abdel-Rahman, S. Koski, 2020, Journal of Cancer Research and Clinical Oncology.

A comparison of medical resource use for 4 chemotherapy regimens as first-line treatment for metastatic colorectal cancer (MCRC): XELOX vs. FOLFOX4 {+/-} bevacizumab (A)

W. Scheithauer, S. Clarke, A. Figer, 2007 .

Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial

J. Hecht, Y. Bang, M. Sawyer, 2017, JAMA oncology.

Does Loosening the Inclusion Criteria of the CROSS Trial Impact Outcomes in the Curative-Intent Trimodality Treatment of Oesophageal and Gastroesophageal Cancer Patients?

A. Abraham, J. Easaw, M. Iafolla, 2022, Clinical oncology (Royal College of Radiologists (Great Britain)).

Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment

L. Mccargar, J. Mackey, T. Reiman, 2009, Clinical Cancer Research.

XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC)

W. Scheithauer, L. Saltz, S. Clarke, 2007 .

Targeting metastatic upper gastrointestinal adenocarcinomas.

Q. Chu, K. King, J. Spratlin, 2011, World journal of clinical oncology.

Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer.

A. Pollett, S. Gill, S. Kamel‐Reid, 2011, Current Oncology.

Clinical determinants of weight loss in patients receiving radiation and chemoirradiation for head and neck cancer: A prospective longitudinal view

L. Mccargar, V. Baracos, K. Olson, 2013, Head & neck.

Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future

Q. Chu, K. King, J. Spratlin, 2010, Oncotarget.

Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers.

J. Mackey, C. Cass, S. Baldwin, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer

D. Tu, H. Kennecke, P. Kavan, 2020, JAMA oncology.

Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.

D. Tu, J. Zalcberg, J. Simes, 2018, The lancet. Gastroenterology & hepatology.

N. Pavlakis, M. Brundage, D. Tu, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 2014.

Duc Hung Le, H. Kennecke, S. Gill, 2015, Current oncology.

Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer

W. Scheithauer, L. Saltz, S. Clarke, 2007 .

CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).

D. Tu, H. Kennecke, P. Kavan, 2019, Journal of Clinical Oncology.

Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer

K. Mulder, O. Abdel-Rahman, S. Koski, 2020, International Journal of Colorectal Disease.

Real-world patterns of adjuvant chemotherapy treatment for patients with resected pancreatic adenocarcinoma

J. Spratlin, O. Abdel-Rahman, S. Koski, 2021, Medical Oncology.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

W. Scheithauer, L. Saltz, A. Figer, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The CCTG CO.26 trial: A phase II randomized study of durvalumab plustremelimumab and best supportive care (BSC) vs BSC alone in patients with advanced colorectal carcinoma (CRC) refractory to standard therapies.

D. Tu, H. Kennecke, D. Jonker, 2017 .

Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment

L. Mccargar, J. Mackey, T. Reiman, 2009, Clinical Cancer Research.

Internet usage among women with breast cancer: an exploratory study.

J Hanson, E. Bruera, J. Mackey, 2000, Clinical breast cancer.

Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients With Refractory Metastatic Colorectal Cancer

E. Titmuss, J. Loree, N. Aucoin, 2023, JAMA network open.